BOSTON, 27th November 2023– Mass General Brigham and Annalise.ai today announced a collaboration to bring together their complementary expertise, capabilities and technology to build and implement AI-enabled diagnostic products. This strategic relationship includes plans to implement Annalise.ai’s comprehensive radiology AI product, called Annalise Triage, across the Mass General Brigham system. The collaboration will be executed through Mass General Brigham’s newly launched AI business office that supports the development of AI-enabled software as medical device products from concept, to prototype, to validation, to clinical adoption.
Leaders from Mass General Brigham and Annalise.ai have identified three core pillars for the collaboration: (i) joint development and/or clinical validation of radiology products; (ii) joint development and/or clinical validation within other diagnostic categories, including multimodal data-based AI products; and (iii) enrichment of Mass General Brigham’s data assets through the use of Annalise.ai’s AI solutions in support of the health system’s clinical and research missions.
Annalise.ai is a global medical imaging AI company, with regulatory clearance for clinical use in over 40 countries including the US. Annalise Triage, an FDA-cleared worklist triage solution that is set to be deployed across the Mass General Brigham system, can automatically and rapidly monitor all chest X-ray (CXR) and non-contrast head CT (NCCTB) exams for time-sensitive critical findings and alert clinicians. Annalise Triage has the most FDA-cleared findings for both of these modalities, and Annalise has also earned breakthrough designation for obstructive hydrocephalus, the only radiology AI company to do so.*
“Diagnosis today is a complex, iterative process requiring data gathering, integration and clinical interpretation from the medical record, imaging tests, labs and other sources. We believe there is significant low-hanging fruit for the use of artificial intelligence to address the intricacies of the diagnostic process,” said Keith Dreyer DO, PhD, Chief Data Science Officer and Chief Imaging Information Officer for Mass General Brigham. “The technologies Mass General Brigham and Annalise.ai will focus on developing through this collaboration may help reduce diagnostic uncertainty and reach a data-driven diagnosis faster, enabling clinicians to assess and recommend optimal treatment pathways to patients sooner.”
